Related Experiment Video
Updated: Jun 24, 2025

Isolation of Cortical Microglia with Preserved Immunophenotype and Functionality From Murine Neonates
Published on: January 30, 2014
Arachidonic Acid Mobilization and Peroxidation Promote Microglial Dysfunction in Aβ Pathology
Da Lin1, Andrew Gold2, Sarah Kaye1
1Department of Neuroscience, The Ohio State University Wexner Medical Center, Columbus, Ohio 43210.
Abstract:
Aberrant increase of arachidonic acid (ARA) has long been implicated in the pathology of Alzheimer's disease (AD), while the underlying causal mechanism remains unclear. In this study, we revealed a link between ARA mobilization and microglial dysfunction in Aβ pathology. Lipidomic analysis of primary microglia from AppNL-GF mice showed a marked increase in free ARA and lysophospholipids (LPLs) along with a decrease in ARA-containing phospholipids, suggesting increased ARA release from phospholipids (PLs). To manipulate ARA-containing PLs in microglia, we genetically deleted lysophosphatidylcholine acyltransferase 3 (Lpcat3), the main enzyme catalyzing the incorporation of ARA into PLs. Loss of microglial Lpcat3 reduced the levels of ARA-containing PLs, free ARA and LPLs, leading to a compensatory increase in monounsaturated fatty acid (MUFA)-containing PLs in both male and female App NL-GF mice. Notably, the reduction of ARA in microglia significantly ameliorated oxidative stress and inflammatory responses while enhancing the phagocytosis of Aβ plaques and promoting the compaction of Aβ deposits. Mechanistically, scRNA seq suggested that LPCAT3 deficiency facilitates phagocytosis by facilitating de novo lipid synthesis while protecting microglia from oxidative damage. Collectively, our study reveals a novel mechanistic link between ARA mobilization and microglial dysfunction in AD. Lowering brain ARA levels through pharmacological or dietary interventions may be a potential therapeutic strategy to slow down AD progression.
Insights
Reducing arachidonic acid (ARA) in brain microglia improves Alzheimer's disease (AD) pathology. This study links ARA mobilization to microglial dysfunction, offering potential therapeutic targets for AD.
Area of Science:
- Neuroscience
- Molecular Biology
- Lipid Metabolism
Background:
- Elevated arachidonic acid (ARA) is linked to Alzheimer's disease (AD) pathology.
- The precise mechanism connecting ARA to microglial dysfunction in AD remains elusive.
Purpose of the Study:
- To investigate the causal link between ARA mobilization and microglial dysfunction in AD.
- To explore the role of lysophosphatidylcholine acyltransferase 3 (LPCAT3) in regulating microglial ARA levels and function.
Main Methods:
- Lipidomic analysis of primary microglia from AppNL-GF mice.
- Genetic deletion of lysophosphatidylcholine acyltransferase 3 (Lpcat3) in microglia.
- Single-cell RNA sequencing (scRNA-seq) to elucidate molecular mechanisms.
Main Results:
- Loss of microglial Lpcat3 reduced ARA and lysophospholipids (LPLs), increasing monounsaturated fatty acid (MUFA)-containing phospholipids.
- Reduced microglial ARA ameliorated oxidative stress, inflammation, and enhanced amyloid-beta (Aβ) phagocytosis and plaque compaction.
- LPCAT3 deficiency promoted de novo lipid synthesis and protected microglia from oxidative damage.
Conclusions:
- A novel mechanistic link between ARA mobilization and microglial dysfunction in AD pathogenesis is revealed.
- Targeting brain ARA levels via pharmacological or dietary interventions may represent a therapeutic strategy for AD.

